Kathleen E Houlahan1, Amirali Salmasi2, Taylor Y Sadun2, Aydin Pooli2, Ely R Felker3, Julie Livingstone4, Vincent Huang4, Steven S Raman3, Preeti Ahuja3, Anthony E Sisk5, Paul C Boutros6, Robert E Reiter7. 1. Ontario Institute for Cancer Research, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada; Vector Institute, Toronto, Canada. 2. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 3. Department of Radiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 4. Ontario Institute for Cancer Research, Toronto, Canada. 5. Department of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. 6. Ontario Institute for Cancer Research, Toronto, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Canada; Vector Institute, Toronto, Canada; Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada; Department of Human Genetics, University of California, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Institute for Precision Health, University of California, Los Angeles, CA, USA; UCLA Department of Human Genetics, 10833 Le Conte Avenue, Los Angeles, CA 90095. Electronic address: Paul.Boutros@oicr.on.ca. 7. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California, Los Angeles, CA, USA; Department of Urology, David Geffen School of Medicine, 300 Stein Plaza, Los Angeles, CA 90095, USA. Electronic address: RReiter@mednet.ucla.edu.
Abstract
Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2 <3) and 20 mpMRI-visible (PI-RADS v2 5) tumors. mpMRI-visible tumors were enriched in hallmarks of nimbosus, an aggressive pathological, molecular, and microenvironmental phenomenon in prostate cancer. These hallmarks included genomes with increased mutation density, a higher prevalence of intraductal carcinoma/cribriform architecture pathology, and altered abundance of 102 transcripts, including overexpression of noncoding RNAs such as SCHLAP1. Multiple small nucleolar RNAs (snoRNAs) were identified, and a snoRNA signature synergized with nimbosus hallmarks to discriminate visible from invisible tumors. These data suggest a confluence of aggressive molecular and microenvironmental phenomena underlie mpMRI visibility of localized prostate cancer. PATIENT SUMMARY: We examined the correlation between tumor biology and magnetic resonance imaging (MRI) visibility in a group of patients with low- intermediate-risk prostate cancer. We observed that MRI findings are associated with biological features of aggressive prostate cancer.
Multiparametric magnetic resonance imaging (mpMRI) has transformed the management of localized prostate cancer by improving identification of clinically significant disease at diagnosis. Approximately 20% of primary prostate tumors are invisible to mpMRI, and we hypothesize that this invisibility reflects fundamental molecular properties of the tumor. We therefore profiled the genomes and transcriptomes of 40 International Society of Urological Pathology grade 2 tumors: 20 mpMRI-invisible (Prostate Imaging-Reporting and Data System [PI-RADS] v2 <3) and 20 mpMRI-visible (PI-RADS v2 5) tumors. mpMRI-visible tumors were enriched in hallmarks of nimbosus, an aggressive pathological, molecular, and microenvironmental phenomenon in prostate cancer. These hallmarks included genomes with increased mutation density, a higher prevalence of intraductal carcinoma/cribriform architecture pathology, and altered abundance of 102 transcripts, including overexpression of noncoding RNAs such as SCHLAP1. Multiple small nucleolar RNAs (snoRNAs) were identified, and a snoRNA signature synergized with nimbosus hallmarks to discriminate visible from invisible tumors. These data suggest a confluence of aggressive molecular and microenvironmental phenomena underlie mpMRI visibility of localized prostate cancer. PATIENT SUMMARY: We examined the correlation between tumor biology and magnetic resonance imaging (MRI) visibility in a group of patients with low- intermediate-risk prostate cancer. We observed that MRI findings are associated with biological features of aggressive prostate cancer.
Authors: Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian Journal: Nat Rev Urol Date: 2020-12-16 Impact factor: 14.432
Authors: Cheyenne Williams; Michael Ahdoot; Michael A Daneshvar; Christian Hague; Andrew R Wilbur; Patrick T Gomella; Joanna Shih; Nabila Khondakar; Nitin Yerram; Sherif Mehralivand; Sandeep Gurram; Minhaj Siddiqui; Paul Pinsky; Howard Parnes; Maria Merino; Bradford Wood; Baris Turkbey; Peter A Pinto Journal: J Urol Date: 2021-08-26 Impact factor: 7.450
Authors: Jack Freeland; Preston D Crowell; Jenna M Giafaglione; Paul C Boutros; Andrew S Goldstein Journal: Cancer Lett Date: 2021-05-28 Impact factor: 8.679
Authors: Joseph M Norris; Benjamin S Simpson; Marina A Parry; Clare Allen; Rhys Ball; Alex Freeman; Daniel Kelly; Alex Kirkham; Veeru Kasivisvanathan; Hayley C Whitaker; Mark Emberton Journal: BMJ Open Date: 2020-01-27 Impact factor: 2.692
Authors: Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R Soule; Arul Chinnaiyan; Eric Small; Jonathan W Simons; William Dahut; Andrea K Miyahira; Himisha Beltran Journal: Nat Cancer Date: 2020-11-17
Authors: Joseph M Norris; Lina M Carmona Echeverria; Simon R J Bott; Louise C Brown; Nick Burns-Cox; Tim Dudderidge; Ahmed El-Shater Bosaily; Eleni Frangou; Alex Freeman; Maneesh Ghei; Alastair Henderson; Richard G Hindley; Richard S Kaplan; Alex Kirkham; Robert Oldroyd; Chris Parker; Raj Persad; Shonit Punwani; Derek J Rosario; Iqbal S Shergill; Vasilis Stavrinides; Mathias Winkler; Hayley C Whitaker; Hashim U Ahmed; Mark Emberton Journal: Eur Urol Date: 2020-05-01 Impact factor: 20.096
Authors: Joseph M Norris; Benjamin S Simpson; Marina A Parry; Clare Allen; Rhys Ball; Alex Freeman; Daniel Kelly; Hyung L Kim; Alex Kirkham; Sungyong You; Veeru Kasivisvanathan; Hayley C Whitaker; Mark Emberton Journal: Eur Urol Open Sci Date: 2020-07